Lit­tle De­ci­phera will hus­tle pos­i­tive PhI­II sur­vival da­ta on lead can­cer drug to the FDA in search of its first OK — shares soar

De­ci­phera has spent the last 5 years po­si­tion­ing it­self as an­oth­er com­mer­cial play­er-to-be in the hec­tic on­col­o­gy are­na, steer­ing its way through a $127 mil­lion IPO $DCPH in 2017, hir­ing Pfiz­er vet Mike Tay­lor as CEO — and then re­plac­ing him with some­one with mar­ket­ing ex­pe­ri­ence last spring.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.